Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 1614

1.

Design Rationale and Development Approach for Pegfilgrastim as a Long-Acting Granulocyte Colony-Stimulating Factor.

Arvedson T, O'Kelly J, Yang BB.

BioDrugs. 2015 May 22. [Epub ahead of print]

PMID:
25998211
2.

[Recombinant granulocyte-colony stimulating factor (filgrastim): optimization of conditions of isolation and purification from inclusion body].

Kononova NV, Iakovlev AV, Zhuravko AM, Pankeev NN, Minaev SV, Bobruskin AI, Mart'ianov VA.

Bioorg Khim. 2014 Sep-Oct;40(5):550-9. Russian.

PMID:
25895350
3.

Biosimilar biologics: never identical but close enough.

Abi-Raad R, Smith BR.

Transfusion. 2015 Feb;55(2):229-31. doi: 10.1111/trf.12961. No abstract available.

PMID:
25683185
4.

First biosimilar drug set to enter US market.

Ledford H.

Nature. 2015 Jan 15;517(7534):253-4. doi: 10.1038/517253a. No abstract available.

PMID:
25592512
5.

Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy.

Kosaka Y, Rai Y, Masuda N, Takano T, Saeki T, Nakamura S, Shimazaki R, Ito Y, Tokuda Y, Tamura K.

Support Care Cancer. 2015 Apr;23(4):1137-43. doi: 10.1007/s00520-014-2597-1. Epub 2015 Jan 10.

6.

Establishment of the first international standard for PEGylated granulocyte colony stimulating factor (PEG-G-CSF): report of an international collaborative study.

Wadhwa M, Bird C, Dougall T, Rigsby P, Bristow A, Thorpe R; participants of the study.

J Immunol Methods. 2015 Jan;416:17-28. doi: 10.1016/j.jim.2014.10.005. Epub 2014 Oct 25.

7.

Fatal stimulation of acute myeloid leukemia blasts by pegfilgrastim.

Duval C, Boucher S, Moulin JC, Gourieux B, Mauvieux L, Leveque D, Herbrecht R.

Anticancer Res. 2014 Nov;34(11):6747-8.

PMID:
25368285
8.

Granulocyte colony-stimulating factors used in clinical practice: PoloNord Registry-Based Cohort Italian Study.

Fagnani D, Isa L, Verga MF, Nova P, Casartelli C, Filipazzi V, Danova M, Farina G, Pugliese P, Fava S, Bertolini A, Cimminiello C, Boracchi P, Marano G, Panzarino C; POLONORD Group.

Tumori. 2014 Sep-Oct;100(5):491-8. doi: 10.1700/1660.18158.

PMID:
25343541
9.

Comparison of the pharmacokinetic and pharmacodynamic properties of two recombinant granulocyte colony-stimulating factor formulations after single subcutaneous administration to healthy volunteers.

Sveikata A, Gumbrevičius G, Seštakauskas K, Kregždytė R, Janulionis V, Fokas V.

Medicina (Kaunas). 2014;50(3):144-9. doi: 10.1016/j.medici.2014.08.001. Epub 2014 Aug 13.

10.

Biosimilars: the science of extrapolation.

Weise M, Kurki P, Wolff-Holz E, Bielsky MC, Schneider CK.

Blood. 2014 Nov 20;124(22):3191-6. doi: 10.1182/blood-2014-06-583617. Epub 2014 Oct 8.

PMID:
25298038
11.

[Experiences with price competition of biosimilar drugs in Hungary].

Hornyák L, Nagy Z, Tálos Z, Endrei D, Ágoston I, Csákvári T, Boncz I.

Acta Pharm Hung. 2014;84(2):83-7. Hungarian.

PMID:
25167704
12.

Technical advance: ascorbic acid induces development of double-positive T cells from human hematopoietic stem cells in the absence of stromal cells.

Huijskens MJ, Walczak M, Koller N, Briedé JJ, Senden-Gijsbers BL, Schnijderberg MC, Bos GM, Germeraad WT.

J Leukoc Biol. 2014 Dec;96(6):1165-75. doi: 10.1189/jlb.1TA0214-121RR. Epub 2014 Aug 25.

PMID:
25157026
13.

Acute myeloid leukemia pretreated with filgrastim mimicking acute promyelocytic leukemia.

Bartlett JR, Lunde JH.

Blood. 2014 Jun 19;123(25):3853. No abstract available.

PMID:
25083521
14.

Biosimilar granulocyte-colony-stimulating factor for mobilization of autologous peripheral blood stem cells in pediatric hematology-oncology patients.

Cesaro S, Tridello G, Prete A, Dallorso S, Cannata E, Massaccesi E, Risso M, De Bortoli M, Caselli D.

Transfusion. 2015 Feb;55(2):246-52. doi: 10.1111/trf.12789. Epub 2014 Jul 29.

PMID:
25070657
15.

Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype.

Hsieh MM, Fitzhugh CD, Weitzel RP, Link ME, Coles WA, Zhao X, Rodgers GP, Powell JD, Tisdale JF.

JAMA. 2014 Jul 2;312(1):48-56. doi: 10.1001/jama.2014.7192.

PMID:
25058217
16.

Amitriptyline-induced agranulocytosis with bone marrow confirmation.

Azadeh N, Kelemen K, Fonseca R.

Clin Lymphoma Myeloma Leuk. 2014 Oct;14(5):e183-5. doi: 10.1016/j.clml.2014.06.001. Epub 2014 Jun 11. No abstract available.

PMID:
25052053
17.

Etanercept-associated transient bone marrow aplasia: a review of the literature and pathogenetic mechanisms.

Kozak N, Friedman J, Schattner A.

Drugs R D. 2014 Jun;14(2):155-8. doi: 10.1007/s40268-014-0050-z. Review.

18.

Purity assessment of recombinant human granulocyte colony-stimulating factor in finished drug product by capillary zone electrophoresis.

Benković G, Skrlin A, Madić T, Debeljak Z, Medić-Šarić M.

Electrophoresis. 2014 Sep;35(18):2608-14. doi: 10.1002/elps.201300552. Epub 2014 Aug 1.

PMID:
24913917
20.

Chromatographic and electrophoretic assessment of Filgrastim biosimilars in pharmaceutical formulations.

Shaltout EL, Al-Ghobashy MA, Fathalla FA, Salem MY.

J Pharm Biomed Anal. 2014 Aug;97:72-80. doi: 10.1016/j.jpba.2014.04.019. Epub 2014 Apr 26.

PMID:
24816160
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk